Skip to main content

Table 1 Baseline characteristics of the subjects included in 1994, before the start of the clinical trial

From: Individuals living in an onchocerciasis focus and treated three-monthly with ivermectin develop fewer new onchocercal nodules than individuals treated annually

 All participants150 µg/kg annually800 µg/kg annually150 µg/kg 3-monthly800 µg/kg 3-monthly
No. of subjects485126122125112
Mean age ± SD36.9 ± 12.036.4 ± 11.438.1 ± 12.436.7 ± 11.936.6 ± 12.3
Mean weight ± SD (kg)63.0 ± 8.062.7 ± 8.264.3 ± 7.162.4 ± 8.562.7 ± 8.0
Mean no. of nodules in 1994 ± SD5.7 ± 2.85.5 ± 2.55.8 ± 2.35.6 ± 3.25.9 ± 2.9
Median no. of nodules in 1994 (IQR)5 (4–7)5 (4–7)6 (4–7)5 (3–7)6 (4–7)
CMFL in the village of residence:
 Low (n, %)50 (10.3)10 (7.9)12 (9.8)18 (14.4)10 (8.9)
 Middle (n, %)135 (27.8)39 (31.0)37 (30.3)30 (24.0)29 (25.9)
 High (n, %)300 (61.9)77 (61.1)73 (59.8)77 (61.6)73 (65.2)
Geometric mean of MFD56.064.750.848.761.8
Median of MFD (IQR)79 (27–171)91 (34–197)71 (26–157)74 (24–143)84 (28–187)
  1. Abbreviations: No, number; SD, standard deviation; IQR, interquartile range; n, number of subjects; CMFL, community microfilarial load; MFD, individual microfilarial density (mf/mg)